Black Diamond Therapeutics (BDTX) Non Operating Income (2019 - 2026)

Black Diamond Therapeutics' Non Operating Income history runs 8 years deep, the most recent figure standing at $2.2 million for Q1 2026.

• Quarterly Non Operating Income rose 10.49% year-over-year to $2.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $10.1 million (up 10.55% YoY) and the FY2025 annual result came in at $9.8 million, up 8.13% from the prior year.
• Non Operating Income was $2.2 million for Q1 2026 at Black Diamond Therapeutics, down from $2.5 million in the prior quarter.
• Across five years, Non Operating Income topped out at $3.0 million in Q4 2022 and bottomed at $172000.0 in Q1 2022.
• A 5-year average of $1.7 million and a median of $2.0 million in 2024 frame the typical range for Non Operating Income.
• Peak annual rise in Non Operating Income reached 1319.72% in 2022, while the deepest fall reached 58.25% in 2022.
• Black Diamond Therapeutics' Non Operating Income stood at $3.0 million in 2022, then plunged by 52.15% to $1.4 million in 2023, then surged by 58.26% to $2.3 million in 2024, then advanced by 8.91% to $2.5 million in 2025, then fell by 10.87% to $2.2 million in 2026.
• Business Quant data shows BDTX's Non Operating Income at $2.2 million in Q1 2026, $2.5 million in Q4 2025, and $2.5 million in Q3 2025.